ArticleESMO open2022

Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors.

S Ochsenreither et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.